MGI Investment Management ApS
MGI Investment Management ApS is 100% owned by Marigold Innovation ApS, which was founded in 2018. MGI Investment Management manages alternative investment funds that invest in biotech projects within medical biotechnology. The projects offered by MGI Investment Management are based on carefully selected research projects from universities and research institutions in Scandinavia. The projects undergo a 1-2 year due diligence process before being presented to MGI Investment Management’ the investment committee. MGI Investment Management is registered as a manager of alternative investment funds with the Danish Financial Supervisory Authority and is subject to AIFM legislation.
150
Number of screened projects
4
Number of investments
2021
First investment
MGI Investment Management’s management
Benny Buchardt Andersen
Peter Horn Møller
CEO & Partner
Chairman of the Board & Partner
Jacob Ørndrup
Board Member & Partner
The investment committee
MGI Investment Management’s investment committee approves and continuously monitors investments on behalf of the fund. Collectively, the members have over 140 years of industry experience in steering investments towards growth and value-creating outcomes.
Peter Horn Møller
Chairman of the investment commitee & partner
Background: Peter holds a master’s degree in biochemistry and organic chemistry, as well as a PhD in medical science.
Peter has over 25 years of experience in IP strategy and licensing and a strong track record of translating advanced research into commercial products. He has held leadership roles as partner and COO in a European patent firm and as part of Novozymes’ IP management team. He played a key role in the spin-out process of Albumedix.
Benny Buchardt Andersen
Vice chairman of the investment commitee & partner
Background: Benny is a C-suite level executive with experience in both Danish and international investments, as well as in building investment organizations.
His career includes roles as co-CEO and CIO at the pension fund PenSam, where he was responsible for managing approximately DKK 130 billion, and as CEO of DEAS Asset Management, an AIFMD-regulated company with around DKK 75 billion under management and operations across the Nordic countries. During Benny’s tenure as CEO, DEAS Asset Management grew from five to over 100 employees.
Jacob Ørndrup
Investment commitee member & Partner
Background: Jacob is a lawyer with more than 25 years of experience in the biotech sector.
Jacob is a Partner at Loeven Law Firm. He has advised a very wide range of clients within biotech, pharma and medtech, ranging from Big Pharma to biotech start-ups and founders. His expertise covers in particular IP, licensing, contract negotiation, and regulatory law.
Charlotte Dyring
Investment commitee member & partner
Background: Charlotte holds an MSc in chemical engineering and a PhD in Biotechnology.
Charlotte has over 30 years of experience in the pharmaceutical and biotech industries, having held positions as both researcher and leader. As co-founder and former CEO of ExpreS2ion Biotechnologies, she led the company through a successful IPO on Nasdaq First North in 2016. She has also built partnerships with pharmaceutical companies and world-renowned universities.
Erik Vinther
Investment commitee member & partner
Background: Erik holds a master’s degree in business economics.
Erik has over 30 years of experience in the pharmaceutical industry, spanning the entire product lifecycle – from early-stage development projects to marketed products. At Novo Nordisk, Erik was responsible for the launch strategy and planning for Wegovy®, which became the first breakthrough for medical weight management generating an annual revenue of USD 4.5 billion just two years after launch. He was also responsible for the relaunch of Levemir®, which, over several years, became the largest contributor to growth for Novo Nordisk.
Are you interested in expanding your investment portfolio? Would you like to learn more about investment opportunities in biotechnology?
Order intro package
MGI Investment Management ApS
Agern Allé 24
2970 Hørsholm
CVR 43867970
AIFM
MGI Investment Management ApS is registered with the Financial Supervisory Authority as a manager of alternative investment funds (AIFM)
FTID: 23321
Auditor
Sønderup I/S
Authorized auditor
CVR 31824559
Terms and conditions
© Marigold Innovation 2025